showing 96% of people with RMS treated with evobrutinib (75mg twice daily) were able to mount an antibody response following two doses of an mRNA COVID-19 vaccine, similar to untreated RMS patients and healthy subjects. The increase in antibody response in sero...
However, it is estimated that due to a combination of Merck's vaccine and PMsv's stability factor allowing storage in a refrigerator (4 °C), a vaccine for normal children will be available sooner in the EEA than would have been the case in the absence of the JV. EurLex-2 (29) ...
I loved my co-workers and the team effort it takes in the pharmaceutical industry to move the business. I loved calling on my customers, that was the highlight of the job, and when things got frustrating with Merck, the customers are what kept me going and motivated. ...
Yu Zou, Leader of GMP Release/Stability from Merck; Thomas Wang, Sales Director and Sarah Wang, Marketing Director at Sartorius Stedim Biotech (Beijing) Co. wuxiapptec.com 无锡生物医药研发外包服务区管委会主任朱小健,副主任华兆哲、副主任曹华强等政府领导,默克生物医药研发外 包负责人PK Tsai博士、...
Rheumatoid arthritis decreases life expectancy; however, this effect on mortality has been decreasing over time and appears to be small. One large cohort study found an excess mortality of only approximately 4 months, which was not apparent until 20 years post-diagnosis (1). Res...
Late-breaking data from apost hocanalysis of vaccinated patients (n=24) in the Phase II OLE were also presented, showing 96% of people with RMS treated with evobrutinib (75mg twice daily) were able to mount an antibody response following two doses of an mRNA COVID-19 vaccine, similar ...
The invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when stored in about the 2-8° C. range while als...
prepared from a temperature sensitive mutant which grew well at 32° C. and not at all at 37° C. or higher. The first vaccine was unsatisfactory as it did not protect against infection when the interval between vaccination and challenge was greater than 4 months. The second vaccine was als...
strategies regarding the development of an HIV vaccine, including but not necessarily limited to a method of identifying a neutralizing antibody; a method for identifying an HIV vaccine candidate(s) (including but not limited to small molecule inhibitors of viral membrane fusion and/or peptide ...
vaccine and/or gene therapy product. The present invention addresses and meets these needs by disclosing an optimized cell culture and virus production process which defines optimal temperature ranges, resulting in an improved virus productivity as well as elimination of intra-batch productivity ...